EAEunyong Ahn

Eunyong Ahn

*This is an algorithmically generated author record based on publicly available information.

Eunyong Ahn has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tumor‐educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation

    by Whi‐An Kwon, Min‐Kyung Lee, Eunyong Ahn, Heeyeon Kim, Yong Sang Song, Taejin Ahn

    Tumor‐educated platelets (TEPs) are emerging as a compelling frontier in liquid biopsy, functioning as dynamic, systemic sensors that sequester and process tumor‐derived biomolecules. This interaction imprints an integrated molecular signature of malignancy—spanning the transcriptome, proteome, lipidome, and crucially, the captured genome—within the circulating platelet population. Recent mechanistic evidence suggests that platelets can sequester extracellular DNA, including circulating tumor DNA (ctDNA), and may thereby act as a relatively protected, time‐integrated reservoir that extends the biological persistence of tumor‐derived fragments beyond the short plasma half‐life (tens of minutes to a few hours). This emerging platelet‐sequestered DNA (pDNA) signal complements more established platelet transcriptomic data; to date, most TEP‐based molecular profiling has relied on RNA and has shown promising performance in identifying diverse solid malignancies, including premalignant lesions, and in some settings facilitating localization of the tissue of origin. However, the translation of these findings into clinical‐grade assays is obstructed by substantial hurdles. Pre‐analytical inconsistencies (e.g., leukocyte/erythrocyte contamination, isolation protocol choice) introduce technical noise and pervasive batch effects that compromise reproducibility. These vulnerabilities have been underscored by failed external validations and poor generalizability of discovery‐phase classifiers in independent cohorts and prospective settings. This review critically dissects the factors influencing TEP diagnostic performance and outlines a concrete roadmap for clinical translation. We argue that rigorous standardization—universal standard operating procedures, harmonized pre‐analytics, and quantitative quality‐control metrics—is the sine qua non for implementation, to be followed by large‐scale, prospective validation trials designed to demonstrate clinical utility and by multi‐omics integration to maximize diagnostic yield.


  • Open Access

    Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9, Figure S10, Figure S11 from Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer

    by Seung Joon Park, Hee Chan Yoo, Eunyong Ahn, Enzhi Luo, Yeabeen Kim, Yulseung Sung, Ya Chun Yu, Kibum Kim, Do Sik Min, Hee Seung Lee, et al.

    Supplementary Figures and Figure Legends for S1 to S11

  • Open Access

    Data from Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer

    by Seung Joon Park, Hee Chan Yoo, Eunyong Ahn, Enzhi Luo, Yeabeen Kim, Yulseung Sung, Ya Chun Yu, Kibum Kim, Do Sik Min, Hee Seung Lee, et al.

    Pancreatic ductal adenocarcinoma (PDAC) exhibits severe hypoxia, which is associated with chemoresistance and worse patient outcome. It has been reported that hypoxia induces metabolic reprogramming in cancer cells. However, it is not well known whether metabolic reprogramming contributes to hypoxia. Here, we established that increased glutamine catabolism is a fundamental mechanism inducing hypoxia, and thus chemoresistance, in PDAC cells. An extracellular matrix component–based in vitro three-dimensional cell printing model with patient-derived PDAC cells that recapitulate the hypoxic status in PDAC tumors showed that chemoresistant PDAC cells exhibit markedly enhanced glutamine catabolism compared with chemoresponsive PDAC cells. The augmented glutamine metabolic flux increased the oxygen consumption rate via mitochondrial oxidative phosphorylation (OXPHOS), promoting hypoxia and hypoxia-induced chemoresistance. Targeting glutaminolysis relieved hypoxia and improved chemotherapy efficacy in vitro and in vivo. This work suggests that targeting the glutaminolysis–OXPHOS–hypoxia axis is a novel therapeutic target for treating patients with chemoresistant PDAC.Significance:Increased glutaminolysis induces hypoxia via oxidative phosphorylation-mediated oxygen consumption and drives chemoresistance in pancreatic cancer, revealing a potential therapeutic strategy of combining glutaminolysis inhibition and chemotherapy to overcome resistance.

  • Open Access

    Catalyzing early ovarian cancer detection: Platelet RNA-based precision screening

    by Eunyong Ahn, Se Ik Kim, Sungmin Park, Sarah Kim, Hyejin Lee, Yeochan Kim, Sangick Park, Suyeon Lee, Dong Won Hwang, Heeyeon Kim, et al.


  • Open Access

    Tailored chemotherapy: Innovative deep‐learning model customizing chemotherapy for high‐grade serous ovarian carcinoma

    by Se Ik Kim, Sangick Park, Eunyong Ahn, Jeunhui Kim, HyunA Jo, Juwon Lee, Untack Cho, Maria Lee, Cheol Lee, Danny N. Dhanasekaran, et al.


  • Impaired BCAA catabolism in adipose tissues promotes age-associated metabolic derangement

    by Hye-Sook Han, Eunyong Ahn, Eun Seo Park, Tom Huh, Seri Choi, Yongmin Kwon, Byeong Hun Choi, Jueun Lee, Yoon Ha Choi, Yujin L. Jeong, et al.

    Adipose tissues are central in controlling metabolic homeostasis and failure in their preservation is associated with age-related metabolic disorders. The exact role of mature adipocytes in this phenomenon remains elusive. Here we describe the role of adipose branched-chain amino acid (BCAA) catabolism in this process. We found that adipocyte-specific Crtc2 knockout protected mice from age-associated metabolic decline. Multiomics analysis revealed that BCAA catabolism was impaired in aged visceral adipose tissues, leading to the activation of mechanistic target of rapamycin complex (mTORC1) signaling and the resultant cellular senescence, which was restored by Crtc2 knockout in adipocytes. Using single-cell RNA sequencing analysis, we found that age-associated decline in adipogenic potential of visceral adipose tissues was reinstated by Crtc2 knockout, via the reduction of BCAA–mTORC1 senescence-associated secretory phenotype axis. Collectively, we propose that perturbation of BCAA catabolism by CRTC2 is critical in instigating age-associated remodeling of adipose tissue and the resultant metabolic decline in vivo.


  • Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer

    by Seung Joon Park, Hee Chan Yoo, Eunyong Ahn, Enzhi Luo, Yeabeen Kim, Yulseung Sung, Ya Chun Yu, Kibum Kim, Do Sik Min, Hee Seung Lee, et al.

    Pancreatic ductal adenocarcinoma (PDAC) exhibits severe hypoxia, which is associated with chemoresistance and worse patient outcome. It has been reported that hypoxia induces metabolic reprogramming in cancer cells. However, it is not well known whether metabolic reprogramming contributes to hypoxia. Here, we established that increased glutamine catabolism is a fundamental mechanism inducing hypoxia, and thus chemoresistance, in PDAC cells. An extracellular matrix component–based in vitro three-dimensional cell printing model with patient-derived PDAC cells that recapitulate the hypoxic status in PDAC tumors showed that chemoresistant PDAC cells exhibit markedly enhanced glutamine catabolism compared with chemoresponsive PDAC cells. The augmented glutamine metabolic flux increased the oxygen consumption rate via mitochondrial oxidative phosphorylation (OXPHOS), promoting hypoxia and hypoxia-induced chemoresistance. Targeting glutaminolysis relieved hypoxia and improved chemotherapy efficacy in vitro and in vivo. This work suggests that targeting the glutaminolysis–OXPHOS–hypoxia axis is a novel therapeutic target for treating patients with chemoresistant PDAC. Significance: Increased glutaminolysis induces hypoxia via oxidative phosphorylation-mediated oxygen consumption and drives chemoresistance in pancreatic cancer, revealing a potential therapeutic strategy of combining glutaminolysis inhibition and chemotherapy to overcome resistance.